Delgado · The Journal of clinical dentistry 2018 · double-blind randomized controlled trial · n=100

A Clinical Investigation of a Dual Zinc plus Arginine Dentifrice in Reducing Established Dental Plaque and Gingivitis Over a Six-Month Period of Product Use.

Cited 20 times in the scientific literature.

Level 2 - randomized trial

Individual double-blind randomized controlled trial

PubMed 30620869 · record verified 2026-08-28

What was done

In a single-center, double-blind, parallel-group randomized clinical trial conducted in Santo Domingo, Dominican Republic, 100 adult subjects were assigned to use either a test dentifrice containing dual zinc (0.96% zinc oxide and zinc citrate), 1.5% arginine, and 1450 ppm fluoride or a regular control dentifrice with 1450 ppm fluoride. Participants brushed twice daily for one minute over a six-month period. Clinical examiners evaluated gingival parameters (gingival index, gingival severity index, interproximal index) and plaque parameters (plaque index, plaque severity index, interproximal index) at baseline, three months, and six months. Ninety-six subjects completed the study.

What was found

At three months, the dual zinc plus arginine group demonstrated statistically significant (p < 0.001) reductions compared to the control group: 18.8% for gingival index, 33.3% for gingival severity index, 19.1% for gingival interproximal index, 11.0% for plaque index, 22.4% for plaque severity index, and 9.8% for plaque interproximal index. At six months, reductions relative to control remained statistically significant (p < 0.001): 26.3% for gingival index, 56.6% for gingival severity index, 29.2% for gingival interproximal index, 30.1% for plaque index, 61.9% for plaque severity index, and 28.0% for plaque interproximal index.

Why it matters

This study provides evidence that supplementing standard fluoride dentifrice with dual zinc and arginine offers incremental efficacy in controlling plaque accumulation and established gingivitis over six months.

Limits

The study was conducted at a single center with a modest sample size (96 completing participants), limiting generalizability. The abstract reports only percentage differences and p-values without absolute index scores, standard deviations, or confidence intervals. Long-term outcomes beyond six months and participant compliance monitoring outside reported instructions were not detailed in the abstract.

Cited by